Europe Nuclear Imaging Market Industry Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Europe's nuclear imaging market encompasses diagnostic technologies such as PET and SPECT scanners, supported by an expanding radiopharmaceutical pipeline and modernizing hospital infrastructure. The market is currently valued at roughly $2.35 billion in 2025 and is on track for sustained expansion through the remainder of the decade. Demand is closely tied to demographic aging and the rising prevalence of chronic and neurodegenerative conditions across the continent.

• •Market valued at approximately $2.35 billion in 2025 with a CAGR near 8.66%.
• •PET and SPECT systems represent the core diagnostic modalities.
• •Germany, France, and the United Kingdom are the leading country markets.

Rising rates of cancer, cardiovascular disease, and neurodegenerative disorders are generating sustained demand for advanced nuclear imaging diagnostics. The clinical adoption of theranostics and targeted radionuclide therapy is accelerating, particularly in oncology centers, while aging populations across Western and Central Europe are increasing referral volumes. Improvements in radiopharmaceutical production, isotope availability, and hospital procurement budgets are further supporting market expansion.

• •Increasing prevalence of cancer, cardiology, and neurodegenerative disease indications.
• •Clinical uptake of theranostics and precision medicine approaches.
• •Stronger radiopharmaceutical supply chains and modernizing imaging infrastructure.

By modality, PET systems account for the majority share of installed equipment, with SPECT continuing to play a significant role in cardiology and bone imaging. Oncology represents the leading clinical application, followed by cardiology and neurology. Germany remains the single largest national market in Europe, with France and the United Kingdom also contributing substantial shares, while Southern and Eastern European countries are expected to grow faster from a smaller base.

• •Oncology is the dominant application segment, with PET leading the modality mix.
• •Germany is the largest country market, followed by France and the United Kingdom.
• •Emerging Southern and Eastern European markets are projected to grow at above-average rates.

What are the recent trends and outlook?

Artificial intelligence is increasingly being embedded into nuclear imaging workflows, supporting faster image reconstruction, automated quantification, and improved diagnostic accuracy. Theranostics is emerging as a defining clinical trend, linking diagnostic imaging with targeted radionuclide therapy for personalized cancer care. Looking ahead, the market is expected to benefit from continued investment in hybrid imaging systems, broader reimbursement coverage, and the rollout of new diagnostic and therapeutic radiopharmaceuticals.

• •AI-driven image analysis and reconstruction tools are gaining traction in clinical practice.
• •Theranostics is expanding rapidly, particularly in oncology centers.
• •Hybrid PET/CT and SPECT/CT systems are seeing broader adoption across European hospitals.